ABGH at AASLD 2021!

When
November 15, 2021
All Day
Event Categories/Tags

ABGH was well and fully represented at AASLD 2021!  Please take a moment to review the amazing scholarship from our members below!

Rotonya M. Carr, MD, FACP

University of Washington
Seattle, WA

 Obesogenic diet and alcohol induce metabolic dysfunction, steatosis, and glucose intolerance, POSTER
 Deletion of ceramide synthase 6 (CerS6) improves hepatic steatosis and glucose homeostasis in ethanol-fed mice, POSTER
 Fecal metabolomic signatures of bile and amino acids distinguish patients with NASH in the REGENERATE study compared to a healthy control population, POSTER OF DISTINCTION
 Long-term clinical outcomes of patients with COVID-19 and chronic liver disease, ORAL
 Diversity Committee Mentoring Session, MENTOR/SPEAKER

Jeremy Louissaint, MD

Columbia University Medical Center
NY, NY

 Patient portal use is associated with lower 90-day readmissions in decompensated cirrhosis, POSTER
 Clinical Practice SIG Poster Debrief, MODERATOR

Emmanuel McDonald DO, MBS

Larkin Community Hospital, South Miami
Miami, FL

 Autoimmune Hepatitis in a Patient with Sarcoidosis, POSTER

Lauren D. Nephew, MD, MAE, MSC

Indiana University School of Medicine
Indianapolis, IN

 Eliminating Health Disparities in Liver Disease, MEET THE EXPERT
 Increasing Rates or Non-Cirrhotic HCC in Black Patients A Multi-Center Cohort Study, ORAL
 Removal of Medicaid Restrictions were Associated with Increased Hepatitis-C Virus Treatment Rates, But Disparities Persist, POSTER

Omar T. Sims, PhD

University of Alabama at Birmingham
Birmingham, AL

 Forecasting Future Hepatitis C Disease Burden Between Non-Hispanic Black, Non-Hispanic White, and Hispanic Older Adults in the United States, POSTER

Ashley Spann, MD, MSACI

Vanderbilt University Medical Center
Nashville, TN

 Meet the Expert: Applying Machine Learning to Liver Disease
 The impact of rural residence, geoeconomics, and health literacy on liver transplant outcomes, POSTER
 Cirrhosis-related sarcopenia may never resolve after liver transplant, POSTER
 Septal ™ is the strongest echocardiographic predictor of the new diagnostic criteria for cirrhotic cardiomyopathy for prediction of major adverse cardiovascular events after liver transplantation, POSTER
 The utility of new versus old diagnostic criteria for cirrhotic cardiomyopathy in predicting major adverse cardiovascular events after liver transplantation, POSTER
 Impact of Cirrhotic Cardiomyopathy on the Development of Acute Kidney Injury Among Patients With Cirrhosis, POSTER
 The association of cirrhotic cardiomyopathy with liver disease severity, POSTER

Kidist K. Yimam, MD

California Pacific Medical Center
San Francisco, CA

 AASLD Global Outreach and Engagement Committee, COMMITTEE MEMBER
 Meeting the Challenges of Liver Health in Africa, SESSION SPEAKER